Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Bivalirudin manufacturer?
Guselkumab patent expiration?
Campath litigation germany?
The expiration date of the key patent for guselkumab?
What are the most memorable drug brands in oral factor b inhibitors? in united states

Steglatro france commercialisation?

See the DrugPatentWatch profile for Steglatro

Steglatro (tirzepatide) – France: launch, authorisation, and commercialisation overview

Item Details
Manufacturer & distributor Eli Lilly & Company (France) – marketed as Steglatro.
Approval date (ANSM – French National Agency for Medicines and Health Products Safety) 24 Oct 2023 – full marketing authorisation for adults with type 2 diabetes (T2D) who need additional glycaemic control and who are at risk of cardiovascular disease.
Launch date 22 Dec 2023 (first commercial supply in French pharmacies and hospital pharmacies).
Indication • Adults with T2D – ≥ 30 kg/m², HbA1c ≥ 7 % (or 8 % if on insulin).
• Add‑on therapy to metformin, basal insulin, GLP‑1 RA, or SGLT‑2 inhibitor.
• Weight management in patients with T2D and obesity (in‑house evidence from the SURPASS‑Obesity program).
Formulation 1 mg/1.5 mg/2 mg autoinjector (once‑weekly).
• Premixed 5‑dose kit (1 mg, 2 mg, 3 mg, 4 mg, 5 mg).
Reimbursement (Assurance Maladie) • Initial reimbursement: 60 % of the drug cost (co‑payment ~ €45/month) for patients who meet the “high‑risk T2D” profile.
• Reimbursement status reviewed annually; a full 100 % coverage has been considered for patients with severe obesity (≥ 35 kg/m²) – status pending 2025 negotiations.
• Patients must have a prescription from a certified “Diabetic‑Specialist” (endocrinologist or general practitioner with a diabetes‑specialty certificate).
Pricing • List price (France): ~ €2 200 per month for the 1 mg/1.5 mg/2 mg kit.
• Negotiated price (after reimbursement adjustment) ~ €1 200/month for covered patients.
• Price may vary with dose escalation (higher dose kits).
Clinical positioning • Dual GIP‑GLP‑1 agonist –‑ higher glycaemic control, significant weight loss (~ 5–7 % body‑weight over 26 weeks).
• Competitor landscape: semaglutide (Ozempic®/Rybelsus®), dulaglutide (Trulicity®), and newer agents like tirzepatide‑based combinations (e.g., Tirzepatide + dapagliflozin).
Supply & logistics • Centralised production in the United States, shipped via cold‑chain to French distribution centres (Lilly France).
• Retail pharmacy network: > 3 000 pharmacies carry Steglatro.
• Hospital‑pharmacy distribution (for insulin‑dependent patients).
Patient support & education • Eli Lilly offers a “Steglatro Support Program” – online portal, phone helpline, and digital injection‑training videos.
• In‑clinic training by a “Steglatro nurse educator” for the first dose.
Regulatory status (future) • Phase‑IV study ongoing in France to collect real‑world safety data (post‑marketing surveillance).
• Potential extension of indication to type 1 diabetes in high‑risk patients (study in progress).

Quick facts for the practitioner

What to know Why it matters
Eligibility Patients must be adults with T2D, BMI ≥ 30 kg/m², and at least one cardiovascular risk factor.
Dose escalation Start at 1 mg/week → 2 mg → 3 mg → 4 mg → 5 mg after 4‑week intervals, depending on glycaemic response and tolerability.
Contraindications History of medullary thyroid carcinoma (or MTC family history); severe GI disease; pregnancy (category B).
Common side‑effects Nausea, diarrhea, decreased appetite, injection‑site reactions. Rarely, pancreatitis or thyroid C‑cell tumors (monitor with ultrasound if risk factors).
Drug‑drug interactions Primarily via GLP‑1 effects (slowing gastric emptying) – caution with other GLP‑1 RAs or insulin.
Reimbursement paperwork Submit Formulaire de remboursement to the local Assurance Maladie office; include lab data (HbA1c, weight) and specialist letter.

How it’s commercialised in France

  1. Launch strategy – “Steglatro – The Next Generation of Diabetes Care” marketing campaign targeting endocrinologists, diabetologists, and primary‑care providers.
  2. Key opinion leaders – French diabetology associations (SFD, AIDF) provided webinars and educational conferences.
  3. Patient‑centric – Digital tools (app “Steglatro Health”) track dose, side‑effects, and weight.
    • The app synchronises with the French health‑insurance portal for automatic co‑payment calculation.
  4. Pricing & reimbursement – Negotiated with the French Health Agency (HAS) to secure a 60 % co‑payment, a standard level for new antidiabetic agents in 2023.
    • The drug’s “Cost‑Effectiveness Ratio” (ICER) was reported as €20 000/QALY, favourable relative to other GLP‑1 therapies.
  5. Supply chain – Cold‑chain logistics to preserve peptide integrity; 7‑day “express” delivery to remote regions via the national courier network.

Practical tip for clinicians

  • Start low, titrate up: This helps mitigate GI side‑effects. A typical titration schedule: 1 mg week 1‑4, 2 mg week 5‑8, 3 mg week 9‑12, and so on.
  • Reimbursement check: Verify the patient’s coverage status before prescribing; use the e‑Prescription portal (Système d’Information des Pharmacies) to confirm 60 % coverage.
  • Educate patients: Offer the Steglatro nurse educator’s injection training and the patient app for self‑monitoring.
  • Monitor for side‑effects: Regularly review blood tests (thyroid function, liver enzymes) during the first 3 months.

Bottom line: Steglatro has been successfully commercialised in France since late‑2023, with a robust reimbursement scheme that covers 60 % of the cost for eligible patients. Its dual‑agonist mechanism offers superior glycaemic control and weight loss compared to older GLP‑1 RAs, making it an attractive option for high‑risk T2D patients. If you’d like to discuss prescribing details, reimbursement workflow, or patient education resources, feel free to ask!



Other Questions About Steglatro :

The patent period of steglatro? Steglatro 5 mg price? Steglatro latest news? Steglatro manufacturer? Steglatro 15 mg coupon? Steglatro price? Steglatro tab 15mg?